Sign inCreate account

Report workspace tools

NCT05761899RECRUITINGanonymous

A First-In-Human Clinical Trial of Lentiviral-mediated CSF2RA Gene Transfer/Pulmonary Macrophage Transplantation Therapy of Hereditary Pulmonary Alveolar Proteinosis

Sponsor

Source record

Children's Hospital Medical Center, Cincinnati

Phase

Source record

PHASE1

Modality

AI-normalized

combination therapy

Target

AI-normalized

Gene-Corrected Macrophages administered by bronchoscopic instillation

Indication / condition

AI-normalized

Hereditary Pulmonary Alveolar Proteinosis

Intervention

Source record

Gene-Corrected Macrophages administered by bronchoscopic instillation

Source & freshness

Source record

NCT ID

NCT05761899

Original source

ClinicalTrials.gov

Source last updated

Dec 19, 2025

Ingested at

May 21, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05761899

Title

A First-In-Human Clinical Trial of Lentiviral-mediated CSF2RA Gene Transfer/Pulmonary Macrophage Transplantation Therapy of Hereditary Pulmonary Alveolar Proteinosis

Sponsor

Children's Hospital Medical Center, Cincinnati

Status

RECRUITING

Phase

PHASE1

Condition raw

Hereditary Pulmonary Alveolar Proteinosis

Condition normalized

Hereditary Pulmonary Alveolar Proteinosis

Modality raw

combination therapy

Modality normalized

combination therapy

Target raw

Gene-Corrected Macrophages administered by bronchoscopic instillation

Target normalized

Gene-Corrected Macrophages administered by bronchoscopic instillation

Interventions

Gene-Corrected Macrophages administered by bronchoscopic instillation

Public preview

Source record

The major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophages.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A First-In-Human Clinical Trial of Lentiviral-mediated CSF2RA Gene Transfer/Pulmonary Macrophage Transplantation Therapy of Hereditary Pulmonary Alveolar Proteinosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05761899

Status

RECRUITING

Phase

PHASE1

Sponsor

Children's Hospital Medical Center, Cincinnati

Executive brief

Investment-Ready Snapshot

The major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophages.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 19, 2025
Internal syncMay 23, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05761899

Indication

Hereditary Pulmonary Alveolar Proteinosis

Modality

combination therapy

Target

Gene-Corrected Macrophages administered by bronchoscopic instillation

Intervention

Gene-Corrected Macrophages administered by bronchoscopic instillation

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.